Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3, after the company entered into an agreement to be acquired by XOMA Royalty (XOMA) for between $1.16 and $1.24 per share in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX: